Clinuvel Pharmaceuticals Limited (CUV.AX)
| Previous close | 15.29 |
| Open | 15.18 |
| Bid | 14.30 x 84100 |
| Ask | 14.60 x 12400 |
| Day's range | 14.34 - 15.28 |
| 52-week range | 12.96 - 21.53 |
| Volume | |
| Avg. volume | 137,238 |
| Market cap | 720.831M |
| Beta (5Y monthly) | 0.74 |
| PE ratio (TTM) | 25.23 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.05 (0.35%) |
| Ex-dividend date | 05 Sept 2023 |
| 1y target est | N/A |
- GlobeNewswire
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company’s unique history and future growth potential at an invitation-only event in Düsseldorf. Managing Director and CEO, Dr Philippe Wolgen shared the Company’s success in establishing profitability over the past seven financial years
- GlobeNewswire
Malibu shines a light on CLINUVEL’s pioneering work in photomedicine
MALIBU, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Leading biotech company CLINUVEL last week joined an intimate event bringing together California’s most prolific investors and philanthropists at the Malibu home of Lady Gaga and Michael Polansky. The event, hosted by Lady Gaga and Mr. Polansky, and Sean Parker and Alexandra Parker, shone a light on the groundbreaking work of CLINUVEL, a global biopharmaceutical firm whose cutting-edge melanocortin therapies transform the lives of patients at th
